Crispr Therapeutics Raises $64m in Series A and Series B Venture Capital Rounds
Summary
In conjunction with the funding, Simeon George, SR One, Ali Behbahani, NEA, and Kurt von Emster, Abingworth, will be joining Crispr’s Board of Directors.Led by Chief Executive Officer Rodger Novak, the company was created to translate CRISPR-Cas9*, a gene-editing technology, into transformative medicines for serious human diseases.Crispr has undertaken translational development programs in several important disease areas with collaborators in Europe and the U.S. and maintains operations in Basel, Switzerland, Stevenage, UK and Cambridge, Massachusetts, USA.*Cas9 is an enzyme that can be programmed with RNA to cut DNA at targeted sites within the genome, enabling the deletion, insertion or correction of target genes, including those that cause diseases, with surgical precision.FinSMEs 29/04/2015 Related News 24/04/2014: Crispr Therapeutics Raises $25M in Series A Funding